Evidence map›Paper›PMID 28362878›Full record

ArticlePloS one2017

Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.

Thibault Guinoiseau, Alain Moreau, Guillaume Hohnadel, Nicole Ngo-Giang-Huong, Celine Brulard, Patrick Vourc'h, Alain Goudeau, Catherine Gaudy-Graffin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Thibault GuinoiseauINSERM U966, Université François Rabelais and CHRU de Tours, Tours, France.
Alain MoreauINSERM U966, Université François Rabelais and CHRU de Tours, Tours, France.
Guillaume HohnadelINSERM U966, Université François Rabelais and CHRU de Tours, Tours, France.
Nicole Ngo-Giang-HuongInstitut de Recherche pour le Développement (IRD) UMI 174 PHPT-Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
Celine BrulardUMR INSERM U930, Université François Rabelais, Tours, France.
Patrick Vourc'hUMR INSERM U930, Université François Rabelais, Tours, France.
Alain GoudeauINSERM U966, Université François Rabelais and CHRU de Tours, Tours, France.
Catherine Gaudy-GraffinINSERM U966, Université François Rabelais and CHRU de Tours, Tours, France.
Université de Tours · FRCentre Hospitalier Universitaire de Tours · FRChiang Mai University · THInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) evolves rapidly in a single host and circulates as a quasispecies wich is a complex mixture of genetically distinct virus's but closely related namely variants. To identify intra-individual diversity and investigate their functional properties in vitro, it is necessary to define their quasispecies composition and isolate the HCV variants. This is possible using single genome amplification (SGA). This technique, based on serially diluted cDNA to amplify a single cDNA molecule (clonal amplicon), has already been used to determine individual HCV diversity. In these studies, positive PCR reactions from SGA were directly sequenced using Sanger technology. The detection of non-clonal amplicons is necessary for excluding them to facilitate further functional analysis. Here, we compared Next Generation Sequencing (NGS) with De Novo assembly and Sanger sequencing for their ability to distinguish clonal and non-clonal amplicons after SGA on one plasma specimen. All amplicons (n = 42) classified as clonal by NGS were also classified as clonal by Sanger sequencing. No double peaks were seen on electropherograms for non-clonal amplicons with position-specific nucleotide variation below 15% by NGS. Altogether, NGS circumvented many of the difficulties encountered when using Sanger sequencing after SGA and is an appropriate tool to reliability select clonal amplicons for further functional studies.

Indexed as

FemaleGenetic VariationGenome, ViralGenomicsGlycoproteinsHepacivirusHigh-Throughput Nucleotide SequencingHumansPolymerase Chain ReactionReproducibility of ResultsSequence Analysis, DNAGlycoproteins

Identifiers

PMID28362878
PMCPMC5376297
OpenAlexW2602774882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.